Acalabrutinib

Summarized by Plex Health
Last Updated: 02 May 2022

Acalabrutinib obstructs the activity of particular enzymes in the body, which can hinder the growth and spread of cancer cells. Acalabrutinib is used to treat mantle cell lymphoma in adults. Acalabrutinib was approved by the United States Food and Drug Administration on an "sped up" basis. Acalabrutinib might also be used for functions not noted in this medication guide. This medicine can make it easier for you to bleed. Call your medical professional or seek emergency clinical attention if you have any bleeding that will not quit. Call your medical professional at once if you have signs of bleeding inside your body, such as: dizziness, weakness, confusion, headache, speech problems, black or bloody stools, pink or brown urine, or divulging blood or vomit that looks like coffee grounds. You should not use acalabrutinib if you are sensitive to it. Taking acalabrutinib may increase your risk of developing other types of cancer, such as skin cancer. Talk to your doctor about this risk and what skin symptoms to expect. It is not recognized whether acalabrutinib will harm an expected child. If you are pregnant or strategy to come to be pregnant, tell your physician. It is not understood whether acalabrutinib passes into breast milk or if it could hurt a nursing baby. Once every 12 hours up until your body no longer reacts to the medicine, Acalabrutinib is usually taken. Take this medication with a complete glass of water. You may take acalabrutinib with or without food. Inform the specialist ahead of time that you are making use of acalabrutinib if you need surgical treatment. While making use of acalabrutinib, you might require regular blood tests.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.

PubChem - CovalentUnitCount

(Table source)
CIDMolecularFormulaMolecularWeightCanonicalSMILESIsomericSMILESInChIInChIKeyIUPACNameXLogPExactMassMonoisotopicMassTPSAComplexityChargeHBondDonorCountHBondAcceptorCountRotatableBondCountHeavyAtomCountIsotopeAtomCountAtomStereoCountDefinedAtomStereoCountUndefinedAtomStereoCountBondStereoCountDefinedBondStereoCountUndefinedBondStereoCountCovalentUnitCount
71226662C26H23N7O2465.5CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5CC#CC(=O)N1CCC[[email protected]]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1WDENQIQQYWYTPO-IBGZPJMESA-N4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide3465.19132300465.1913230011984502643501100001
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.

logo

Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.